// App-Quantinova.ai

P1-19-11 : Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010)

Researchers

Presenter

  • Rebecca Roylance

Principal Investigators

  • Lucy Kilburn

  • Sarah Kernaghan

  • Andrew M Wardley

  • Iain Macpherson

  • Richard D Baird

  • Peter Stephens

  • Olga Oikonomidou

  • Jeremy P Braybrooke

  • Mark Tuthill

  • Jacinta Abraham

  • Matthew C Winter

  • Belinda Kingston

  • Katie Wilkinson

  • Alistair Ring

  • Judith M Bliss

  • Nicholas Turner

Medical Centers

  • University College London Hospitals NHS Foundation Trust & NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom

  • Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom

  • The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Manchester, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Cancer Research UK, Cambridge Research Institute, Cambridge, United Kingdom

  • Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom

  • Edinburgh Cancer Research UK Center, Western General Hospital, Edinburgh, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust, Wells Somerset, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Velindre NHS Trust, Cardiff, United Kingdom

  • The Royal Hallamshire Hospital, Sheffield Teaching Hospitals, NHS Foundation Trust, Sheffield, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • AKT Serine

  • Circulating DNA

Drug/Treatment

  • Fulvestrant

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved